Cargando…

Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter

BACKGROUND: Neoadjuvant chemotherapy (NAC) is used in patients with breast cancer to reduce tumor focus, metastatic risk, and patient mortality. Monitoring NAC effects is necessary to capture resistant patients and stop or change treatment. The existing methods for evaluating NAC results have some l...

Descripción completa

Detalles Bibliográficos
Autores principales: Piotrzkowska-Wróblewska, Hanna, Dobruch-Sobczak, Katarzyna, Klimonda, Ziemowit, Karwat, Piotr, Roszkowska-Purska, Katarzyna, Gumowska, Magdalena, Litniewski, Jerzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417657/
https://www.ncbi.nlm.nih.gov/pubmed/30870478
http://dx.doi.org/10.1371/journal.pone.0213749
_version_ 1783403600024698880
author Piotrzkowska-Wróblewska, Hanna
Dobruch-Sobczak, Katarzyna
Klimonda, Ziemowit
Karwat, Piotr
Roszkowska-Purska, Katarzyna
Gumowska, Magdalena
Litniewski, Jerzy
author_facet Piotrzkowska-Wróblewska, Hanna
Dobruch-Sobczak, Katarzyna
Klimonda, Ziemowit
Karwat, Piotr
Roszkowska-Purska, Katarzyna
Gumowska, Magdalena
Litniewski, Jerzy
author_sort Piotrzkowska-Wróblewska, Hanna
collection PubMed
description BACKGROUND: Neoadjuvant chemotherapy (NAC) is used in patients with breast cancer to reduce tumor focus, metastatic risk, and patient mortality. Monitoring NAC effects is necessary to capture resistant patients and stop or change treatment. The existing methods for evaluating NAC results have some limitations. The aim of this study was to assess the tumor response at an early stage, after the first doses of the NAC, based on the variability of the backscattered ultrasound energy, and backscatter statistics. The backscatter statistics has not previously been used to monitor NAC effects. METHODS: The B-mode ultrasound images and raw radio frequency data from breast tumors were obtained using an ultrasound scanner before chemotherapy and 1 week after each NAC cycle. The study included twenty-four malignant breast cancers diagnosed in sixteen patients and qualified for neoadjuvant treatment before surgery. The shape parameter of the homodyned K distribution and integrated backscatter, along with the tumor size in the longest dimension, were determined based on ultrasound data and used as markers for NAC response. Cancer tumors were assigned to responding and non-responding groups, according to histopathological evaluation, which was a reference in assessing the utility of markers. Statistical analysis was performed to rate the ability of markers to predict the final NAC response based on data obtained after subsequent therapeutic doses. RESULTS: Statistically significant differences (p<0.05) between groups were obtained after 2, 3, 4, and 5 doses of NAC for quantitative ultrasound markers and after 5 doses for the assessment based on maximum tumor dimension. Statistical analysis showed that, after the second and third NAC courses the classification based on integrated backscatter marker was characterized by an AUC of 0.69 and 0.82, respectively. The introduction of the second quantitative marker describing the statistical properties of scattering increased the corresponding AUC values to 0.82 and 0.91. CONCLUSIONS: Quantitative ultrasound information can characterize the tumor's pathological response better and at an earlier stage of therapy than the assessment of the reduction of its dimensions. The introduction of statistical parameters of ultrasonic backscatter to monitor the effects of chemotherapy can increase the effectiveness of monitoring and contribute to a better personalization of NAC therapy.
format Online
Article
Text
id pubmed-6417657
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-64176572019-04-01 Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter Piotrzkowska-Wróblewska, Hanna Dobruch-Sobczak, Katarzyna Klimonda, Ziemowit Karwat, Piotr Roszkowska-Purska, Katarzyna Gumowska, Magdalena Litniewski, Jerzy PLoS One Research Article BACKGROUND: Neoadjuvant chemotherapy (NAC) is used in patients with breast cancer to reduce tumor focus, metastatic risk, and patient mortality. Monitoring NAC effects is necessary to capture resistant patients and stop or change treatment. The existing methods for evaluating NAC results have some limitations. The aim of this study was to assess the tumor response at an early stage, after the first doses of the NAC, based on the variability of the backscattered ultrasound energy, and backscatter statistics. The backscatter statistics has not previously been used to monitor NAC effects. METHODS: The B-mode ultrasound images and raw radio frequency data from breast tumors were obtained using an ultrasound scanner before chemotherapy and 1 week after each NAC cycle. The study included twenty-four malignant breast cancers diagnosed in sixteen patients and qualified for neoadjuvant treatment before surgery. The shape parameter of the homodyned K distribution and integrated backscatter, along with the tumor size in the longest dimension, were determined based on ultrasound data and used as markers for NAC response. Cancer tumors were assigned to responding and non-responding groups, according to histopathological evaluation, which was a reference in assessing the utility of markers. Statistical analysis was performed to rate the ability of markers to predict the final NAC response based on data obtained after subsequent therapeutic doses. RESULTS: Statistically significant differences (p<0.05) between groups were obtained after 2, 3, 4, and 5 doses of NAC for quantitative ultrasound markers and after 5 doses for the assessment based on maximum tumor dimension. Statistical analysis showed that, after the second and third NAC courses the classification based on integrated backscatter marker was characterized by an AUC of 0.69 and 0.82, respectively. The introduction of the second quantitative marker describing the statistical properties of scattering increased the corresponding AUC values to 0.82 and 0.91. CONCLUSIONS: Quantitative ultrasound information can characterize the tumor's pathological response better and at an earlier stage of therapy than the assessment of the reduction of its dimensions. The introduction of statistical parameters of ultrasonic backscatter to monitor the effects of chemotherapy can increase the effectiveness of monitoring and contribute to a better personalization of NAC therapy. Public Library of Science 2019-03-14 /pmc/articles/PMC6417657/ /pubmed/30870478 http://dx.doi.org/10.1371/journal.pone.0213749 Text en © 2019 Piotrzkowska-Wróblewska et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Piotrzkowska-Wróblewska, Hanna
Dobruch-Sobczak, Katarzyna
Klimonda, Ziemowit
Karwat, Piotr
Roszkowska-Purska, Katarzyna
Gumowska, Magdalena
Litniewski, Jerzy
Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter
title Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter
title_full Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter
title_fullStr Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter
title_full_unstemmed Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter
title_short Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter
title_sort monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417657/
https://www.ncbi.nlm.nih.gov/pubmed/30870478
http://dx.doi.org/10.1371/journal.pone.0213749
work_keys_str_mv AT piotrzkowskawroblewskahanna monitoringbreastcancerresponsetoneoadjuvantchemotherapywithultrasoundsignalstatisticsandintegratedbackscatter
AT dobruchsobczakkatarzyna monitoringbreastcancerresponsetoneoadjuvantchemotherapywithultrasoundsignalstatisticsandintegratedbackscatter
AT klimondaziemowit monitoringbreastcancerresponsetoneoadjuvantchemotherapywithultrasoundsignalstatisticsandintegratedbackscatter
AT karwatpiotr monitoringbreastcancerresponsetoneoadjuvantchemotherapywithultrasoundsignalstatisticsandintegratedbackscatter
AT roszkowskapurskakatarzyna monitoringbreastcancerresponsetoneoadjuvantchemotherapywithultrasoundsignalstatisticsandintegratedbackscatter
AT gumowskamagdalena monitoringbreastcancerresponsetoneoadjuvantchemotherapywithultrasoundsignalstatisticsandintegratedbackscatter
AT litniewskijerzy monitoringbreastcancerresponsetoneoadjuvantchemotherapywithultrasoundsignalstatisticsandintegratedbackscatter